18 Mar 2026 · to Health
asked the Minister for Health the specific steps that are being taken to ensure the HSE recognises the time-critical nature of Friedreich’s ataxia during the current price negotiations for Skyclarys; and if she will make a statement on the matter. [18770/26
18 Mar 2026 · to Health
Clarke asked the Minister for Health to outline the current status of the reimbursement application for skyclarys (omaveloxolone) for the treatment of Friedreich’s ataxia; if she will provide a detailed update of ongoing engagement between the HSE and the manufacturer; and the way in which the commitments
18 Mar 2026 · to Health
Minister for Health the steps being taken to ensure that the HSE recognises and responds to the time-critical nature of Friedreich’s ataxia during the current price negotiations for skyclarys; the way in which the commitments, which are outlined in the National Rare Disease Strategy
18 Mar 2026 · to Health
Deputy Paul Lawless asked the Minister for Health the measures in place to ensure HSE price talks for skyclarys take account for Friedreich’s ataxia time-sensitive progression. [19311/26
18 Mar 2026 · to Health
Deputy Alan Kelly asked the Minister for Health if she will commit to make the treatment omaveloxolone available for suffers of Friedreich’s ataxia; and if she will make a statement on the matter. [19427/26
18 Mar 2026 · to Health
position regarding a timeline for the completion of the assessment of the proposal for reimbursement of Skyclarys for patients with Friedreich’s ataxia; and if she will make a statement on the matter. [19446/26
18 Mar 2026 · to Health
Health if any submissions can be consider as part of the assessment of the proposal for reimbursement of Skyclarys for patients with Friedreich’s ataxia; and if she will make a statement on the matter. [19447/26
18 Mar 2026 · to Health
Health if she will facilitate a meeting with the campaign group that are seeking State funded reimbursement of skyclarys for patients with Friedreich’s ataxia; and if she will make a statement on the matter. [19448/26
18 Mar 2026 · to Health
meeting between the relevant Department staff and the campaign group that are seeking State funded reimbursement of skyclarys for patients with Friedreich’s ataxia; and if she will make a statement on the matter. [19449/26
18 Mar 2026 · to Health
Deputy Keira Keogh asked the Minister for Health the position regarding the availability of Skyclarys (Omaveloxolone) for those who are living with Friedreich’s ataxia; and if she will make a statement on the matter. [19485/26
18 Mar 2026 · to Health
Minister for Health the specific actions being taken to ensure that the HSE recognises and responds to the time-critical nature of Friedreich’s ataxia in the ongoing price negotiations for Skyclarys (Omaveloxolone); the way in which the commitments contained within the National Rare Disease Strategy
18 Mar 2026 · to Health
consideration has been given to prioritise the reimbursement of Skyclarys (omaveloxolone) under the current drugs reimbursement process for the treatment for Friedreich's Ataxia; and if she will make a statement on the matter. [19753/26
18 Mar 2026 · to Health
ensure that the HSE prioritises a conclusion to the Skyclarys reimbursement negotiations, given that it is the only available treatment for Friedreich's ataxia disease and represents a clear unmet need under the National Rare Disease Strategy 2025-2030; if she believes the current delay in concluding negotiations
18 Mar 2026 · to Health
asked the Minister for Health the steps being taken to ensure that the HSE recognises and responds to the time-critical nature of Friedreichs Ataxia during the current price negotiations for Skyclarys; and if she will make a statement on the matter. [20158/26
18 Mar 2026 · to Health
IPHA Framework Agreement which aims for a 180-day decision timeline being applied in the case of ensuring Friedreichs Ataxia patients in Ireland can access Skyclarys; and to prevent further delays in addressing this clear unmet need; and if she will make a statement on the matter. [20159/26
18 Mar 2026 · to Health
Minister for Health the steps being taken to ensure that the HSE recognises and responds to the time-critical nature of Friedreich's ataxia during the current price negotiations for Skyclarys; the way in which the commitments outlined in the National Rare Disease Strategy
18 Mar 2026 · to Health
Minister for Health the steps being taken to ensure that the HSE recognises and responds to the time-critical nature of Friedreich's ataxia during the current price negotiations for Skyclarys; and if she will make a statement on the matter. [20251/26
18 Mar 2026 · to Health
asked the Minister for Health the specific steps the HSE is taking to ensure that the time critical and progressive nature of Friedreich's Ataxia is fully recognised and acted upon during the ongoing price and reimbursement negotiations for skyclarys, given the significant risk of irreversible decline
18 Mar 2026 · to Health
implemented in practice for rare disease medicines; and the reason this timeline has not been met in the case of skyclarys for Friedreich's Ataxia patients. [20490/26
18 Mar 2026 · to Health
considered establishing an Early Access Programme for skyclarys, in light of the progressive and time sensitive nature of Friedreich's Ataxia, so that patients can access the treatment while reimbursement negotiations are ongoing. [20491/26
18 Mar 2026 · to Health
Health the position regarding the current reimbursement process for Omaveloxolone, considering the time-sensitive nature of the condition for those with Friedreich's ataxia; and if she will make a statement on the matter. [20597/26
18 Mar 2026 · to Health
prioritises a conclusion to the Skyclarys reimbursement negotiations, given that it is the only available treatment for a progressive disease Friedreich's Ataxia (FA), which currently can be classed as having an ‘unmet need’, as outlined in the National Rare Disease Strategy 2025 – 2030; whether she believes
18 Mar 2026 · to Health
Deputy Aengus Ó Snodaigh asked the Minister for Health the reason access to Friedreich's Ataxia is not available on the medical card or licenced for the drug reimbursement scheme for patients in the State; and if she will make a statement on the matter. [20816/26
5 Mar 2026 · to Health
Conor Sheehan asked the Minister for Health the specific steps being taken to ensure the HSE considers the time-critical nature of Friedreich’s ataxia during the current price negotiations for Skyclarys, the only drug approved for treatment of this condition, given the 570 days since the application
4 Mar 2026 · to Health
Deputy Johnny Guirke asked the Minister for Health regarding the reimbursement of Skyclarys (omaveloxolone), the only approved treatment for Friedreich’s Ataxia (details supplied), the specific steps being taken to ensure the HSE considers the "time-critical" nature of FA during the current price negotiations for Skyclarys